Get started
Author

A.A. Chanan‐Khan

Observed names: A Chanan-Khan, A. Chanan-Khan, Ascher Chanan-Khan
OpenAlex ID: A5023367406
Treatment of Immunoglobulin Light Chain Amyloidosis
2015 · Angela Dispenzieri, Francis Buadi, et al. · Mayo Clinic Proceedings · 121
PDF
Integrated Analysis: Outcomes of Ibrutinib‐treated Patients With Chronic Lymphocytic Leukemia/small Lymphocytic Leukemia (cll/sll) With High‐risk Prognostic Factors
2017 · T.J. Kipps, G. Fraser, et al. · Hematological Oncology · 12
PDF
P04: Daratumumab Plus Bortezomib and Dexamethasone Versus Bortezomib and Dexamethasone Alone in Patients With Previously Treated Multiple Myeloma: Overall Survival Results From the Phase 3 Castor Trial
2022 · P Sonneveld, A Chanan-Khan, et al. · HemaSphere · 7
Pb1888: Efficacy of First-line Treatment for Chronic Lymphocytic Leukemia: a Bayesiannetwork Meta-analysis.
2022 · A. Chanan-Khan, K. Yang, et al. · HemaSphere · 1
Pf596 Efficacy and Safety of Daratumumab, Bortezomib, and Dexamethasone (d‐vd) in Relapsed or Refractory Multiple Myeloma (rrmm): Updated Subgroup Analysis of Castor Based on Cytogenetic Risk
2019 · K. Weisel, A. Spencer, et al. · HemaSphere
Works count: 5
Citation count: 141
H-index: 3
I10-index: 2
Year
Topic
Type